These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 31481328)
1. The End of the Beginning: The Journey to Molecular Therapies for Spinal Muscular Atrophy. Pacak CA; Kang PB Pediatr Neurol; 2020 Jan; 102():1-2. PubMed ID: 31481328 [No Abstract] [Full Text] [Related]
2. Pre-Nusinersen Hospitalization Costs of Children With Spinal Muscular Atrophy. Lee M; França UL; Graham RJ; McManus ML Pediatr Neurol; 2019 Mar; 92():3-5. PubMed ID: 30591237 [No Abstract] [Full Text] [Related]
3. [Gene-based therapies of spinal muscular atrophy: a piece of history of medicine]. Braun S Med Sci (Paris); 2020 Feb; 36(2):141-146. PubMed ID: 32129750 [TBL] [Abstract][Full Text] [Related]
4. More is needed to complement the available therapies of spinal muscular atrophy. Singh RN Future Med Chem; 2019 Nov; 11(22):2873-2876. PubMed ID: 31668092 [No Abstract] [Full Text] [Related]
5. Gene therapy for spinomuscular atrophy: a biomedical advance, a missed opportunity for more equitable drug pricing. Friedmann T Gene Ther; 2017 Sep; 24(9):503-505. PubMed ID: 28639617 [TBL] [Abstract][Full Text] [Related]
6. Spinal Muscular Atrophy in the Age of Gene Therapy. Williams L AACN Adv Crit Care; 2020 Mar; 31(1):86-91. PubMed ID: 32168519 [No Abstract] [Full Text] [Related]
7. Future avenues for therapy development for spinal muscular atrophy. Groen EJN Expert Opin Drug Discov; 2018 Oct; 13(10):899-902. PubMed ID: 30124076 [No Abstract] [Full Text] [Related]
8. Zolgensma - one-time gene therapy for spinal muscular atrophy. Med Lett Drugs Ther; 2019 Jul; 61(1577):113-114. PubMed ID: 31381549 [No Abstract] [Full Text] [Related]